MARK2 and glioma: MAP3K1 is a 196‐kDa serine/threonine kinase that is activated by various stimuli and cell stresses, including growth factors, cytokines, and microtubule disruption.35 Our present study showed elevated MAP3K1 expression in glioma, which is conversely associated with a poor prognosis and therapeutic resistance in glioma.